50% versus 70%: is there a difference between these BCL2 cut-offs in immunohistochemistry for diffuse large B-cell lymphomas (DLBCL)?

Table 4 “Double- expressor” lymphomas and clinical evolution, according to the BCL2 cut-off adopted in the IHC (50% or 70%)

	> 50% (N = 27)	p-value*	> 70% (N = 22)	p-value*
Non-germinal center-like	14 (51.8%)	0.575	10 (45.4%)	0.298
Stage III/IV	13 (48.1%)	0.266	11 (50%)	0.206
BM^a	3 (11.1%)	0.224	3 (13.6%)	0.432
CNS^b	2 (7.4%)	0.566	2 (9.0%)	0.426
Death^c	7 (28%)	0.030	6/20 (30%)	0.099

ISSN: 2520-8454